Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Specified Drug Use resulTs survEy of lpragLifLozin treAtment in type2 Diabetes Patients: LONG-TERM (STELLA-LONG TERM)

NCT02479399 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02479399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02479399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Specified Drug Use resulTs survEy of lpragLifLozin treAtment in type2 Diabetes Patients: LONG-TERM (STELLA-LONG TERM)
Lead sponsor
Astellas Pharma Inc
Phase
Observational
Overall status
Completed
Start date
July 17, 2014
Completion date
October 16, 2018
Enrollment
11,412 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes